Cantor Fitzgerald Lowers Earnings Estimates for Codexis

Codexis, Inc. (NASDAQ:CDXS) – Cantor Fitzgerald reduced their FY2025 earnings estimates for shares of Codexis in a research report issued to clients and investors on Monday, March 10th. Cantor Fitzgerald analyst K. Kluska now expects that the biotechnology company will post earnings of ($0.60) per share for the year, down from their previous forecast of ($0.49). Cantor Fitzgerald has a “Overweight” rating and a $11.00 price objective on the stock. The consensus estimate for Codexis’ current full-year earnings is ($0.77) per share.

Codexis (NASDAQ:CDXS) last posted its earnings results on Thursday, February 27th. The biotechnology company reported ($0.13) earnings per share for the quarter, missing the consensus estimate of ($0.04) by ($0.09). The firm had revenue of $21.46 million during the quarter, compared to analyst estimates of $27.41 million. Codexis had a negative net margin of 96.35% and a negative return on equity of 71.56%.

Codexis Stock Performance

NASDAQ:CDXS opened at $2.76 on Wednesday. The company has a debt-to-equity ratio of 0.39, a current ratio of 3.21 and a quick ratio of 3.15. The firm has a market capitalization of $228.63 million, a price-to-earnings ratio of -3.17 and a beta of 2.12. The company’s 50-day moving average is $4.21 and its two-hundred day moving average is $3.95. Codexis has a 1-year low of $2.47 and a 1-year high of $6.08.

Hedge Funds Weigh In On Codexis

Several large investors have recently made changes to their positions in CDXS. Summit Investment Advisors Inc. lifted its holdings in shares of Codexis by 81.4% in the 4th quarter. Summit Investment Advisors Inc. now owns 8,428 shares of the biotechnology company’s stock worth $40,000 after acquiring an additional 3,783 shares during the last quarter. Wolverine Trading LLC acquired a new position in shares of Codexis in the 4th quarter worth approximately $56,000. Fiduciary Trust Co acquired a new position in shares of Codexis in the 4th quarter worth approximately $65,000. Intech Investment Management LLC acquired a new position in shares of Codexis in the 3rd quarter worth approximately $66,000. Finally, Group One Trading LLC acquired a new position in shares of Codexis in the 4th quarter worth approximately $73,000. 78.54% of the stock is currently owned by institutional investors and hedge funds.

Codexis Company Profile

Codexis, Inc discovers, develops, and sells enzymes and other proteins. The company operates through two segments, Performance Enzymes and Novel Biotherapeutics. It offers biocatalyst products and services. The company also provides biocatalyst screening and protein engineering services. In addition, it offers CodeEvolver, a technology platform, which helps in developing and delivering biocatalysts that perform chemical transformations and enhance the efficiency and productivity of manufacturing processes.